Remedy Plan Therapeutics Announces AACR 2026 Presentations
Remedy Plan Therapeutics will bring a broad slate of AACR presentations centered on RPT1G, its “hyperbolic” NAMPT inhibitor now...
Bioxodes Shares Pivotal Trial Design for BIOX-101 in ICH
Bioxodes is moving BIOX-101 into an adaptive Phase 2b/3 study in intracerebral hemorrhage with functional outcome (mRS) as the...
AIM Plans Pivotal Phase 3 Trial for Pancreatic Cancer
In late-stage pancreatic ductal adenocarcinoma, rintatolimod (Ampligen) has generated early clinical signals across multiple settings: a Dutch named-patient program...
Surging Storm Therapeutics Secures $56M for Sarcoma Drug
In earlier-stage testing, STC-15, an oral METTL3 inhibitor, produced durable tumor regressions across multiple sarcoma subtypes as monotherapy. Building...
Inhibikase Enrolls First Patient in Phase 3 PAH Study
IMPROVE-PAH is a two-part adaptive Phase 3 program testing IKT-001, an oral prodrug of imatinib, in up to 180...
Incyclix Bio’s Hope: A Surging $5M for Cancer Trial
Incyclix Bio secured an additional $5 million extension to its Series B from Hatteras Venture Partners to advance INX-315,...
COACH trial: hGH accelerates CNP benefits in achondroplasia
At Week 52 in the Phase 2 COACH trial, once-weekly TransCon CNP plus once-weekly TransCon hGH delivered a mean...
Radiopharm Advances to Cohort 3 in Phase 1 Clinical Trial
Radiopharm Theranostics’ Phase 1 HEAT trial cleared its second safety gate, with the independent monitoring committee recommending dose escalation...
Incyclix Bio’s Promising Cancer Trial Gets New $5M Fund
Incyclix Bio secured an additional $5 million for its Series B to extend development of INX-315, a selective CDK2...
Pioneering gammaCore nVNS Study for PTSD Enrolls First Patient
electroCore’s gammaCore non-invasive vagus nerve stimulation device has entered PTSD clinical testing with the first eight of a planned...